Corvus Pharmaceuticals Inc. | Mutual Funds
Mutual Funds that own Corvus Pharmaceuticals Inc.
Fidelity Select Biotechnology Portfolio
1,842,725
6.31%
-82,842
0.22%
07/31/2018
T Rowe Price Health Sciences Fund
585,784
2%
-2,171
0.05%
06/30/2018
T Rowe Price New Horizons Fund
558,192
1.91%
-3,616
0.03%
06/30/2018
Fidelity Advisor Biotechnology Fund
530,555
1.82%
-24,229
0.2%
07/31/2018
Vanguard Total Stock Market Index Fund
394,400
1.35%
0
0%
07/31/2018
T Rowe Price Small Cap Stock Fund
349,756
1.2%
-2,100
0.04%
06/30/2018
iShares Nasdaq Biotechnology ETF
335,373
1.14%
-4,389
0.04%
09/06/2018
iShares Russell 2000 ETF
290,125
0.99%
-156
0.01%
09/06/2018
T Rowe Price Institutional Small Cap Stock Fund
163,289
0.56%
0
0.04%
06/30/2018
Vanguard Extended Market Index Fund
152,346
0.52%
5,000
0%
07/31/2018
| Address |
863 Mitten Road
Burlingame California 94010
United States
|
|
Employees
|
- |
| Website |
http://www.corvuspharma.com |
| Updated |
07/08/2019 |
| Corvus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of small molecule and antibody agents that target crucial enzymes and proteins in the immune system to treat patients with cancer. Its product pipeline includes Adenosine A2A Receptor Antagonist CPI-444, Adenosine Production Inhibitor Anti-CD73, Adenosine A2B Receptor Antagonist, ITK Inhibitor, and Myeloid Cell Suppression. The company was founded by Richard A. |
